Capsule composition for use as immunogen against Campylobacter jejuni
Inventors
Guerry, Patricia • Monteiro, Mario Artur
Assignees
Publication Number
US-9308246-B2
Publication Date
2016-04-12
Expiration Date
2031-05-27
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Immunogenic compositions, and method of using the compositions to elicit an immune response against Campylobacter jejuni. The compositions are isolated polysaccharide polymers derived from Campylobacter jejuni capsule.
Core Innovation
The invention relates to immunogenic compositions comprising isolated capsule polysaccharide polymers derived from Campylobacter jejuni. These compositions are designed to elicit an immune response against C. jejuni without causing the autoimmune complications associated with lipooligosaccharides (LOS). The capsule polysaccharides can be unconjugated or conjugated to carrier proteins to enhance immunogenicity.
Campylobacter jejuni is a major cause of diarrheal disease worldwide, with significant impact on human health and military personnel. There are currently no licensed vaccines against C. jejuni, primarily because molecular mimicry between LOS cores and human gangliosides leads to autoimmune reactions such as Guillain Barre Syndrome (GBS). The invention addresses this by focusing on capsule polysaccharides, which lack this mimicry and are thus safer immunogens for vaccine development.
Claims Coverage
The patent includes two independent claims covering immunogenic compositions and methods of inducing immune responses against Campylobacter jejuni.
Immunogenic composition of isolated capsule carbohydrate polymers from specific C. jejuni strains
The immunogenic composition is composed of one or more isolated capsule carbohydrate polymers derived from Campylobacter jejuni strains HS10 and HS15, excluding lipooligosaccharides, and comprising specified polysaccharide formulas.
Conjugation of capsule carbohydrate polymers to carrier molecules
The capsule carbohydrate polymers are conjugated to carrier proteins, such as cross reacting material 197 (CRM197) or tetanus toxoid, via specific sugar residues, including arabinose or 6-deoxy-heptose monosaccharides.
Method of inducing an immune response against Campylobacter jejuni
A method of inducing immunity by administering the immunogenic composition to a mammal through various routes (oral, nasal, subcutaneous, intradermal, transdermal, transcutaneous, intramuscular, or rectal) optionally with adjuvants to enhance the immune response.
The independent claims cover immunogenic compositions excluding LOS, conjugation techniques to carrier proteins, and methods of immunization against C. jejuni using these compositions with specified administration routes and adjuvants.
Stated Advantages
The capsule polysaccharide compositions are immunogenic and capable of conferring protection against Campylobacter jejuni diarrhea without inducing Guillain Barre Syndrome.
Conjugation to carrier proteins can improve the immune response, especially in populations such as infants who typically have poor polysaccharide immunogenicity.
Documented Applications
Vaccine formulations comprising isolated capsule polysaccharide structures from C. jejuni strains HS10, HS13, and HS15 for inducing protective immunity against diarrheal disease.
Use of conjugated or unconjugated capsule polysaccharide compositions as immunogens administered via oral, nasal, subcutaneous, intradermal, transdermal, transcutaneous, intramuscular, or rectal routes, optionally with adjuvants.
Interested in licensing this patent?